SCHEMBL3005641

SCHEMBL3005641

O=S(=O)(c1cccc(Cl)c1Cl)N1CCN(c2nc(-c3cccc(Br)c3)cs2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
LMNA P02545 4/20 0.53
KMT2A Q03164 4/20 0.53
ALDH1A1 P00352 4/20 0.53
MEN1 O00255 3/20 0.53
MAPK1 P28482 3/20 0.50
USP2 O75604 1/20 0.50
RECQL P46063 1/20 0.50
HSD17B10 Q99714 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.47
RAB9A P51151 4/20 0.46
TSHR P16473 1/20 0.44
AR P10275 1/20 0.43
KDM1A O60341 1/20 0.42
MAOA P21397 1/20 0.42
NPC1 O15118 1/20 0.42
HPGD P15428 1/20 0.42
HK1 P19367 1/20 0.42
HKDC1 Q2TB90 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008857 0.93 MAPT (0.56) MAPTSMN1; SMN2LMNAKMT2AALDH1A1
SCHEMBL15671704 0.89 SMN1; SMN2 (0.52) MAPTSMN1; SMN2LMNAKMT2AALDH1A1
SCHEMBL3005738 0.89 LMNA (0.64) MAPTSMN1; SMN2LMNAKMT2AALDH1A1
SCHEMBL3011207 0.88 MAPT (0.53) MAPTSMN1; SMN2LMNAKMT2AALDH1A1
SCHEMBL3018650 0.88 LMNA (0.57) MAPTSMN1; SMN2LMNAKMT2AALDH1A1
SCHEMBL3014513 0.88 MAPT (0.57) MAPTSMN1; SMN2LMNAKMT2AALDH1A1
SCHEMBL3013564 0.87 MAPT (0.50) MAPTSMN1; SMN2LMNAKMT2AALDH1A1
SCHEMBL3016174 0.87 MEN1 (0.50) MAPTSMN1; SMN2LMNAKMT2AALDH1A1
SCHEMBL3010147 0.87 SMN1; SMN2 (0.56) MAPTSMN1; SMN2LMNAKMT2AALDH1A1
SCHEMBL3011306 0.85 MAPT (0.62) MAPTSMN1; SMN2LMNAKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885SMN1; SMN2 1/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.